• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[开始高效抗逆转录病毒治疗后发生的局灶性分枝杆菌性淋巴结炎]

[Focal mycobacterial lymphadenitis after starting highly active antiretroviral therapy].

作者信息

Schwietert M, Battegay M

机构信息

Medizinische Universitäts-Poliklinik, Kantonsspital Basel.

出版信息

Dtsch Med Wochenschr. 1999 Jan 22;124(3):45-8. doi: 10.1055/s-2007-1024241.

DOI:10.1055/s-2007-1024241
PMID:9987485
Abstract

HISTORY AND FINDINGS

A 30-year-old man with a known HIV infection for 7 years presented for treatment with antiretroviral drugs. He was known to have had herpes zoster, oral hairy leukoplakia and recurrent Candida stomatitis, but was otherwise without symptoms.

INVESTIGATIONS

The CD4 lymphocyte count was 19 cells/mm3 and there were 41,000 HIV-RNA copies/ml.

DIAGNOSIS, TREATMENT AND COURSE: The HIV infection was in CDC stage B3, indicating the need for combined antiretroviral treatment. A week after starting stavudine, saquinavir and ritonavir he had to be admitted because of nausea and vomiting, colicky abdominal pain, diarrhea, fever up to 39 degrees C and a rise of C-reactive protein to 207 mg/dl. Bacteriological examination of feces and biopsy of an enlarged retroperitoneal lymph node revealed atypical mycobacteria. Antituberculosis treatment was started. The CD4 cell count rose to 56/mm3 and the viral count fell to 11,000/ml. Each time after initiating a different antiviral regimen the symptoms recurred.

CONCLUSIONS

This case illustrates an atypical manifestation of on opportunistic infection: during combined antiviral treatment the CD4 cell count rose and thus precipitated an heretofore subclinical mycobacterial infection with focal lymphadenitis. If, on starting antiretroviral treatment at a late HIV stage, new symptoms develop within 1-3 weeks, one should consider drug-induced side effects or the onset of an opportunistic infection that has become manifest as the result of an improved immunological state.

摘要

病史与检查结果

一名30岁男性,已知感染HIV 7年,前来接受抗逆转录病毒药物治疗。他曾患带状疱疹、口腔毛状白斑和复发性念珠菌性口炎,但除此之外并无其他症状。

检查

CD4淋巴细胞计数为19个/立方毫米,HIV-RNA拷贝数为41,000/毫升。

诊断、治疗与病程:HIV感染处于美国疾病控制与预防中心(CDC)的B3期,表明需要进行联合抗逆转录病毒治疗。开始使用司他夫定、沙奎那韦和利托那韦一周后,他因恶心、呕吐、绞痛性腹痛、腹泻、体温高达39摄氏度以及C反应蛋白升至207毫克/分升而入院。粪便细菌学检查和肿大的腹膜后淋巴结活检显示非典型分枝杆菌。开始抗结核治疗。CD4细胞计数升至56/立方毫米,病毒载量降至11,000/毫升。每次更换不同的抗病毒治疗方案后,症状都会复发。

结论

该病例说明了一种机会性感染的非典型表现:在联合抗病毒治疗期间,CD4细胞计数上升,从而引发了此前亚临床的分枝杆菌感染并伴有局灶性淋巴结炎。如果在HIV晚期开始抗逆转录病毒治疗时,在1 - 3周内出现新症状,应考虑药物引起的副作用或因免疫状态改善而显现的机会性感染的发生。

相似文献

1
[Focal mycobacterial lymphadenitis after starting highly active antiretroviral therapy].[开始高效抗逆转录病毒治疗后发生的局灶性分枝杆菌性淋巴结炎]
Dtsch Med Wochenschr. 1999 Jan 22;124(3):45-8. doi: 10.1055/s-2007-1024241.
2
The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.接受抗逆转录病毒治疗3年后病毒载量无法检测的患者每日一次服用沙奎那韦/利托那韦的48周疗效。
HIV Med. 2005 Mar;6(2):122-8. doi: 10.1111/j.1468-1293.2005.00274.x.
3
Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.每日一次使用沙奎那韦/利托那韦进行一线治疗的长期疗效与安全性。
Antivir Ther. 2008;13(3):375-80.
4
A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.初治泰国患者每日一次服用沙奎那韦/利托那韦联合两种核苷类逆转录酶抑制剂的疗效与安全性的前瞻性研究。
Antivir Ther. 2005;10(6):761-7.
5
Adherence over 48 weeks in an antiretroviral clinical trial: variable within patients, affected by toxicities and independently predictive of virological response.抗逆转录病毒临床试验中48周的依从性:患者体内存在差异,受毒性影响且独立预测病毒学反应。
Antivir Ther. 2001 Jun;6(2):97-103.
6
Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.抗逆转录病毒治疗。成人HIV感染:定义更明确的一线治疗。
Prescrire Int. 2004 Aug;13(72):144-50.
7
Long-term efficacy and safety of twice-daily saquinavir soft gelatin capsules (SGC), with or without nelfinavir, and three times daily saquinavir-SGC, in triple combination therapy for HIV infection: 100-week follow-up.每日两次服用沙奎那韦软胶囊(SGC),联合或不联合奈非那韦,以及每日三次服用沙奎那韦-SGC,用于HIV感染三联联合治疗的长期疗效和安全性:100周随访
Antivir Ther. 2003 Feb;8(1):37-42.
8
[Diagnosis and treatment of mycobacterial infections in patients with HIV/AIDS].[人类免疫缺陷病毒/艾滋病患者分枝杆菌感染的诊断与治疗]
Enferm Infecc Microbiol Clin. 1998;16 Suppl 1:20-8.
9
The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.LOPSAQ研究:含洛匹那韦/利托那韦加沙奎那韦的增强型双蛋白酶抑制剂方案在无额外抗逆转录病毒治疗情况下的48周分析。
J Antimicrob Chemother. 2006 Nov;58(5):1024-30. doi: 10.1093/jac/dkl375. Epub 2006 Sep 6.
10
HAART and Mycobacterium avium complex in an HIV infected patient with severe factor VII deficiency.
Haemophilia. 2000 Mar;6(2):116-7. doi: 10.1046/j.1365-2516.2000.00373.x.